Ocrelizumab treatment in patients with progressive multiple sclerosis: a single-center real-world experience

被引：0
|
作者：
Cellerino, Maria [1 ]
Boffa, Giacomo [1 ]
Lapucci, Caterina [2 ]
Sbragia, Elvira [1 ]
Bruschi, Nicolo [1 ]
Mancuso, Elisabetta [1 ]
Tazza, Francesco [1 ]
Poire, Ilaria [3 ]
Laroni, Alice [3 ]
Capello, Elisabetta [3 ]
Uccelli, Antonio [1 ,3 ]
Novi, Giovanni [3 ]
Inglese, Matilde [1 ]
机构：
[1] Univ Genoa, DINOGMI, Genoa, Italy
[2] Lab Neurosci Sperimentali, Osped Policlin San Martino IRCCS, Genoa, Italy
[3] Dept Neurol, Osped Policlin San Martino IRCCS, Genoa, Italy
来源：
NEUROLOGY | 2021年 / 96卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
2504
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Ocrelizumab in people with primary progressive multiple sclerosis: A real-world multicentric study
    Skoric, Magdalena Krbot
    Kes, Vanja Basic
    Grbic, Nevena
    Lazibat, Ines
    Pavelin, Sanda
    Zubonja, Tea Mirosevic
    Komso, Milica
    Piskac, Spomenka Kidemet
    Abicic, Ana
    Piskac, Dominik
    Adamec, Ivan
    Barun, Barbara
    Gabelic, Tereza
    Habek, Mario
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 89
  • [22] Real-world experience with Ocrelizumab in Multiple Sclerosis patients: Two years follow up in Qatar
    Yousuf, Wajiha
    Ganesan, Gowrii Saswathy
    Humos, Basel
    Baig, Tehniyat
    Canibano, Beatriz
    Deleu, Dirk
    NEUROLOGY, 2021, 96 (15)
  • [23] Switching from ocrelizumab to ofatumumab in multiple sclerosis: a monocenter real-world experience
    Axhausen, Franziska
    Baumgart, Romy
    Winter, Pia
    Mueck, Anna
    Huttner, Hagen
    Wolff, Stephanie
    Pfeuffer, Steffen
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1099 - 1100
  • [24] Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers
    Diem, L.
    Ovchinnikov, A.
    Friedli, C.
    Hammer, H.
    Kamber, N.
    Chan, A.
    Salmen, A.
    Findling, O.
    Hoepner, R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 86
  • [25] Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario
    Lorefice, Lorena
    Mellino, Paolo
    Frau, Jessica
    Coghe, Giancarlo
    Fenu, Giuseppe
    Cocco, Eleonora
    NEUROLOGICAL SCIENCES, 2024, 45 (08) : 3951 - 3959
  • [26] Real-world experience of secondary progressive multiple sclerosis patients treated with siponimod
    Totaro, Rocco
    Borriello, Giovanna
    Marinelli, Fabiana
    Bianco, Assunta
    Evangelista, Luana
    Mirabella, Massimiliano
    Cicia, Alessandra
    Marini, Carmine
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1240 - 1241
  • [27] Real-World Clinical Outcomes in Elderly Chinese Patients with Multiple Myeloma: A Single-Center Experience
    Qian, Xifeng
    Chen, Heng
    Xia, Jun
    Wang, Jing
    Zhou, Xin
    Guo, Hongfeng
    MEDICAL SCIENCE MONITOR, 2018, 24 : 5887 - 5893
  • [28] Real world evidence with Ocrelizumab in progressive and relapsing multiple sclerosis
    Meca-Lallana, V.
    Diaz-Perez, C.
    Aguirre, C.
    del Rio, B.
    Martin, R.
    del Rio, B.
    Carabajal, E.
    Vivancos, J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 97 - 98
  • [29] A real-world analysis of ocrelizumab treatment patterns among multiple sclerosis patients in saskatchewan, canada
    Saini, A.
    Poliakov, I.
    Knox, K.
    Kahovec, C.
    Jata, A.
    Macgowan, S.
    Levin, M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 323 - 323
  • [30] Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study
    Carmen Alcalá
    Carlos Quintanilla-Bordás
    Francisco Gascón
    Ángel Perez Sempere
    Laura Navarro
    María Carcelén-Gadea
    Lamberto Landete
    Javier Mallada
    Emmanuel Cañizares
    Antonio Belenguer
    Sara Carratalá
    José Andrés Domínguez
    Francisco Carlos Pérez-Miralles
    Sara Gil-Perotín
    Raquel Gasqué
    Laura Cubas
    Jéssica Castillo
    Bonaventura Casanova
    Journal of Neurology, 2022, 269 : 3676 - 3681
12345